Table of Contents

• Clinical trial overview
• Conditions being studied
• Trial designs and phases
• Who can participate
• Main outcomes being measured
• What the trial data are trying to show

Clinical trial overview

Two Phase 3 studies are listed for Lorundrostat, both focused on hypertension, which means high blood pressure.^[1][1] One study is a randomized, double-blind, placebo-controlled, parallel-arm, multicenter trial, and the other is an open-label extension study.^[1] The trial records show that the main goals are to test efficacy, safety, and tolerability in people with uncontrolled or resistant hypertension.^[1][1]

Conditions being studied

The first study targets uncontrolled and resistant hypertension, meaning blood pressure that stays high despite treatment.^[1] The extension study includes subjects with hypertension and also looks at a subgroup with albuminuria, which means protein in the urine.^[1] This matters because the trial is not only looking at blood pressure, but also at a possible kidney-related marker in some participants.^[1]

Trial designs and phases

Both records describe Phase 3 research, which is a late stage of clinical testing.^{[1][1] The main trial is randomized and double-blind, so participants are assigned to groups by chance and neither the participants nor the study team know who receives which treatment during the study period.[1] It also uses placebo, which is a look-alike tablet without active study drug, to compare results fairly.[1]}

The extension study is open-label, which means the treatment is known to the participant and the research team.^[1] It is designed to follow people longer and assess whether the treatment effect lasts over time.^[1] The record also mentions a randomized treatment withdrawal substudy, which tests what happens when treatment is removed in a controlled way.^[1]

Who can participate

The studies include subjects with hypertension, especially those with uncontrolled or resistant hypertension.^{[1][1] The extension study also includes people who were already enrolled in the parent studies, showing that some participants continue into longer follow-up.[1] The trial data do not list every detailed eligibility rule, but they clearly focus on adults already living with difficult-to-control blood pressure.[1][1]}

Main outcomes being measured

The main outcome in the randomized Phase 3 study is the change in automated office blood pressure (AOBP) systolic blood pressure, or SBP, at Week 6 compared with baseline.^[1] Baseline means the starting point before the study treatment effect is measured.^[1] In simple terms, the study is asking whether Lorundrostat lowers the top blood pressure number more than placebo.^[1]

The extension study measures several blood pressure outcomes over time, including change from baseline to Week 12 and later follow-up points.^[1] It also measures the change in AOBP SBP in a randomized treatment withdrawal substudy, which helps show whether the blood pressure benefit continues when treatment is changed.^[1] Another outcome is the percent change in urine albumin creatinine ratio, or UACR, in participants who had albuminuria at the parent study baseline.^[1]

The extension study also focuses on long-term safety and tolerability.^[1] Safety means how well the treatment can be used without causing major harm, while tolerability means how well people can handle it overall.^[1] These outcomes are important because hypertension treatment often needs to be used for a long time.^[1]

What the trial data are trying to show

The trial records show that Lorundrostat is being studied as an add-on treatment for blood pressure control in people whose hypertension is hard to manage.^[1] The main question is whether it can improve systolic blood pressure compared with placebo and whether the effect lasts during longer follow-up.^{[1][1] The extension study adds a second layer of research by looking at longer-term use, treatment withdrawal, and kidney-related markers such as albuminuria.[1]}

Because one study is completed and the extension study is authorised, the records suggest that Lorundrostat has already been tested in a major late-stage program for hypertension.^{[1][1] The available data focus on whether the treatment can lower blood pressure, maintain that effect, and remain acceptable for longer use in the study population.[1][1]}